

From: [Jeremy LaJoice](#)
To: [AGO - High Cost Prescription Drugs](#)
Subject: RE: New Drug Report - Pricing Over \$670
Date: Friday, April 17, 2020 2:07:55 PM

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

Also, please note the AWP is 870.31. The WAC is actually 725.26.

[Jeremy LaJoice](#)

Prescription Analytics, Inc.
823 E Sumner Street | Hartford, WI 53027
Office: 262.706.0439

From: Jeremy LaJoice
Sent: Friday, April 17, 2020 1:04 PM
To: 'AGO.highcostprescriptiondrugs@vermont.gov' <AGO.highcostprescriptiondrugs@vermont.gov>
Subject: RE: New Drug Report - Pricing Over \$670

Additional Details are below on the recent launch of AvKare's product.

1. a description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;
 - a. This drug is marketed as a typical generic drug would be, through the use of wholesalers to distributor the product. There is not a significant marketing campaign or active patient facing marketing.
2. the estimated volume of patients who may be prescribed the drug;
 - a. 274 - Monthly usage based on AvKare's expected sale volume and patient base. This is a generic drug - AvKare does not have information related to overall market usage.
3. whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval; and
 - a. No priority designation or priority review
4. the date and price of acquisition if the drug was not developed by the manufacturer
 - a. This is a generic drug - acquisition price doesn't appear to be relevant since it's not a typical situation in which there was a one time purchase payment for the development/acquisition rights to manufacturer the drug. This is not public information as well.

Please let me know if you have any questions or require any additional clarification/information!

[Jeremy LaJoice](#)

Prescription Analytics, Inc.

823 E Sumner Street | Hartford, WI 53027
Office: 262.706.0439

From: Jeremy LaJoice
Sent: Friday, April 03, 2020 3:31 PM
To: AGO.highcostprescriptiondrugs@vermont.gov
Subject: New Drug Report - Pricing Over \$670

Please note that AvKare launched NDC 50268-0165-15 with a WAC of \$870.31 which will be available for sale starting April 1, 2020. A detailed report will follow.

[Jeremy LaJoice](#)
Prescription Analytics, Inc.
823 E Sumner Street | Hartford, WI 53027
Office: 262.706.0439